Transcranial Pulse Stimulation. a Potential Treatment for Early Dementia

Launched by FRANCESCA PISTOIA · Dec 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Transcranial Pulse Stimulation (TPS) to see if it can help improve thinking and memory skills in people with early-stage Alzheimer’s disease. Alzheimer’s is a condition that affects memory and the ability to think, and currently, there are no effective treatments to slow it down. The goal of this study is to explore whether this innovative technique can make a positive difference for patients.

To join the trial, participants must be at least 18 years old, have been diagnosed with early dementia for at least a year, and be able to give their consent to participate. However, individuals who have certain medical conditions or health issues that could affect their ability to undergo tests or the treatment will not be eligible. During the trial, participants can expect to receive TPS and undergo assessments to track any changes in their cognitive abilities. This study is currently recruiting participants, and it aims to enhance care for those living with Alzheimer’s disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age\>18 years
• • diagnosis of early dementia according to current international guidelines
• • disease duration of at least 12 months
• • consent to participate in the study.
• Exclusion Criteria:
• • medical instability interfering with standard neurological assessment
• • any contraindication to preliminary MRI for MR-based real-time neuronavigation
• • comorbidities which may interfere with cognitive status
• • any contraindication to Transcranial Pulse Stimulation.